The scientific research surrounding the supplement of silymarin, primarily derived from milk thistle, provides some promising insights for its potential benefits in managing diabetes. Several studies indicate that silymarin and its active component, silibinin, may help lower blood glucose levels and reduce insulin resistance in various models, including diabetic rats. One systematic review found that silibinin could improve inflammatory responses and tackle complications related to diabetes, such as liver damage and neuropathy [3]. However, while these results are encouraging, they stress the necessity for more robust and structured clinical trials to validate the efficacy of silymarin as a reliable treatment option for diabetes.
On the other hand, some research shows limited impact on key diabetes metrics. For instance, while silymarin may improve insulin resistance slightly, it does not significantly alter fasting insulin levels [1]. Moreover, in various tests involving animal models, while silymarin showed effects on metabolic health, it did not consistently manage blood sugar levels or improve pancreatic function [11]. Therefore, while there are indications that silymarin could be beneficial in supporting diabetes management, further studies are warranted to fully delineate its effectiveness and applicability in human subjects.